AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential Payoff
Photo by Dr_Microbe/iStock via Getty Images
AbCellera Biologics (ABCL) has had a very interesting first 6 months as a public company. The shares rocketed out of the IPO to an eye watering $58 and seem to have settled into a $23 to $33 range over the last few months.
Data by YCharts
Many investors have latched onto the COVID-19 antibody therapies the company is producing with Eli Lilly (LLY), however to me, this is a bit of a distraction from the larger picture. In this article I would like to discuss…
